



## **Integra LifeSciences Announces Launch of Newdeal Foot and Ankle Implants and United States Introduction of the CALCANEA(R) Plate**

PLAINSBORO, N.J., Feb. 16, 2005 (PRIMEZONE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it has begun selling Newdeal® foot and ankle products in the United States through its Reconstructive Surgery sales force. Integra LifeSciences also announced the first United States release of the CALCANEA® Plate, a new product of Newdeal SA available exclusively through Integra LifeSciences.

The Newdeal products will join Integra LifeSciences' other products for reconstruction and repair of the extremities, including the INTEGRA® Dermal Regeneration Template, the INTEGRA™ Bilayer Matrix Wound Dressing, the NeuraGen™ Nerve Guide, and the NeuraWrap™ Nerve Protector. Integra LifeSciences will sell the Newdeal products through its Reconstructive Surgery sales force. Integra LifeSciences plans to increase the size of its United States Reconstructive Surgery sales force to more than forty representatives by the end of 2005.

The CALCANEA® calcaneal fracture fixation plate is specifically designed to treat fractures of the hind foot. Its unique combined features include variable thickness and angle-stabilized and/or adjustable fixation. The CALCANEA® Plate, along with the entire Newdeal product portfolio, will be on display at the American Academy of Orthopaedic Surgeons convention next week, February 23 - 25, in Washington, D.C.

"The CALCANEA® Plate is an exciting extension of our Newdeal portfolio of products for the repair and reconstruction of the foot," said Stuart M. Essig, President and Chief Executive Officer of Integra LifeSciences. "With Newdeal's implants and instruments and our soft tissue repair and regeneration products such as the NeuraGen™ Nerve Guide, the NeuraWrap™ Nerve Protector and the INTEGRA™ Bilayer Matrix Wound Dressing, Integra LifeSciences provides orthopedic and podiatric surgeons with a unique range of products that address most of the pathologies of the foot and ankle."

Newdeal, based in Lyon, France, is a leading developer and manufacturer of specialty implants and instruments specifically designed for foot and ankle surgery. Newdeal's products include a wide range of products for the forefoot, the mid-foot and the hind foot, including the Bold® Screw, the Spin® screw, the Uniclip® staple, the Hallu-Fix® plate system and the HINTEGRA® total ankle prosthesis. The company sells its products through a direct sales force in the United States, France, Belgium and the Netherlands, and through distributors in more than 30 countries. Newdeal's target physicians include orthopedic surgeons specializing in injuries of the foot, ankle and extremities, as well as podiatric surgeons, of which there are 3,200 and 2,400, respectively, in the United States. Newdeal's current products address a worldwide market of approximately \$500 million.

Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, reconstructive surgery and general surgery. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. Our corporate headquarters are in Plainsboro, New Jersey, and we have manufacturing and research facilities located throughout the world. We have approximately 1,200 employees. Please visit our website at (<http://www.Integra-LS.com>) and Newdeal's website at (<http://www.newdeal.info>).

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning expectations for future financial results, and statements concerning the future use of the CALCANEA® Plate. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, Integra's ability to secure market acceptance for new products may affect actual results. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Factors That May Affect Our Future Performance" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2003, and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

**CONTACT:**  
Integra LifeSciences Holdings Corporation

John B. Henneman, III  
Executive Vice President  
Chief Administrative Officer  
(609) 936-2481

[jhenneman@Integra-LS.com](mailto:jhenneman@Integra-LS.com)

Maria Platsis  
Director of Corporate Development  
and Investor Relations  
(609) 936-2333  
[mplatsis@Integra-LS.com](mailto:mplatsis@Integra-LS.com)